- Home
- KRKR vs NXTC Comparison
KRKR vs NXTC Comparison
Compare KRKR & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRKR
- NXTC
- Stock Information
- Founded
- KRKR 2010
- NXTC 2015
- Country
- KRKR China
- NXTC United States
- Employees
- KRKR N/A
- NXTC N/A
- Industry
- KRKR Business Services
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- KRKR Consumer Discretionary
- NXTC Health Care
- Exchange
- KRKR Nasdaq
- NXTC Nasdaq
- Market Cap
- KRKR 11.7M
- NXTC 13.9M
- IPO Year
- KRKR 2019
- NXTC 2019
- Fundamental
- Price
- KRKR $5.90
- NXTC $0.50
- Analyst Decision
- KRKR
- NXTC Strong Buy
- Analyst Count
- KRKR 0
- NXTC 2
- Target Price
- KRKR N/A
- NXTC $3.50
- AVG Volume (30 Days)
- KRKR 3.8K
- NXTC 147.5K
- Earning Date
- KRKR 03-11-2025
- NXTC 07-31-2025
- Dividend Yield
- KRKR N/A
- NXTC N/A
- EPS Growth
- KRKR N/A
- NXTC N/A
- EPS
- KRKR N/A
- NXTC N/A
- Revenue
- KRKR $31,657,328.00
- NXTC N/A
- Revenue This Year
- KRKR $182.55
- NXTC N/A
- Revenue Next Year
- KRKR N/A
- NXTC N/A
- P/E Ratio
- KRKR N/A
- NXTC N/A
- Revenue Growth
- KRKR N/A
- NXTC N/A
- 52 Week Low
- KRKR $2.76
- NXTC $0.22
- 52 Week High
- KRKR $12.99
- NXTC $1.82
- Technical
- Relative Strength Index (RSI)
- KRKR 67.04
- NXTC 55.61
- Support Level
- KRKR $5.68
- NXTC $0.47
- Resistance Level
- KRKR $5.91
- NXTC $0.52
- Average True Range (ATR)
- KRKR 0.08
- NXTC 0.04
- MACD
- KRKR -0.06
- NXTC 0.00
- Stochastic Oscillator
- KRKR 55.00
- NXTC 61.67
About KRKR 36Kr Holdings Inc.
36KR Holdings Inc is a holding company and conducts its business mainly through its subsidiaries, a VIE, and subsidiaries of the VIE. The Group is engaging in providing content and business services to new economy participants in the PRC. Its content production process includes content creation, content editing, screening and monitoring, and content distribution. The Group mainly generates revenues from providing online advertising services, enterprise value-added services, and subscription services. The Group's principal operations and geographic markets are substantially located in PRC.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.